US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Latigo Biotherapeutics (LTGO): IPO Gets a Healthy Start, Then Loses Its Pain Relief

Latigo Biotherapeutics (LTGO): Biotech Sets IPO Terms Behind Non-Opioid Pain Pipeline

IPOs and Secondary Offerings

Equity Capital Markets

Latigo Biotherapeutics / Equity Capital Markets

<ul>
<li>Differentiated pipeline: LTG-001 has generated compelling Phase 2 data, supporting its potential as a fast-acting, opioid-sparing therapy for acute pain.</li>
<li>Positive setup: Books are scheduled to close today with strong momentum, positioning the company favorably heading into Friday's expected market debut.</li>
<li>High-Quality sponsorship: Westlake BioPartners, Foresite Capital, and 5AM Ventures remain significant shareholders, providing experienced biotech backing.</li>
</ul>


Differentiated pipeline: LTG-001 has generated compelling Phase 2 data, supporting its potential as a fast-acting, opioid-sparing therapy for acute pain.
Positive setup: Books are scheduled to close today with strong momentum, positioning the company favorably heading into Friday's expected market debut.
High-Quality sponsorship: Westlake BioPartners, Foresite Capital, and 5AM Ventures remain significant shareholders, providing experienced biotech backing.


Latigo Biotherapeutics (LTGO): Taking the Sting Out of Pain: Latigo Draws IPO Demand